文献速递淋巴瘤

纳武利尤单抗联合R-CHOP治疗初治弥漫性大B细胞淋巴瘤的安全性与疗效评估

Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy.
PubMed 文献 · Blood Adv · 2025-01-01

约20%的弥漫性大B细胞淋巴瘤存在涉及程序性死亡配体1和2(PD-L1/PD-L2)基因座的异常,这为在一线治疗中探索PD-1检查点抑制剂以改善高危患者结局提供了依据。这项1b期研究采用预处理方法评估纳武利尤单抗联合R-CHOP的安全性及初步疗效,共入组33例患者,其中25例可评估毒性、22例可评估疗效。估计18个月总生存率和无进展生存率分别为95.4%和72.7%,治疗相关不良事件与既往纳武利尤单抗和R-CHOP报告相比无显著差异,患者报告结局未提示加用纳武利尤单抗导致生活质量指标恶化。

要点

  • 1b期研究评估纳武利尤单抗联合R-CHOP治疗初治弥漫性大B细胞淋巴瘤。
  • 入组33例,可评估毒性25例、疗效22例;估计18个月OS 95.4%、PFS 72.7%。
  • 治疗相关不良事件与既往纳武利尤单抗和R-CHOP报告相比无显著差异。

核心结论

  • 纳武利尤单抗联合R-CHOP采用预处理方法在初治弥漫性大B细胞淋巴瘤中显示出可评估的安全性和初步疗效。

研究设计与样本

  • 1b期研究,采用预处理方法,评估纳武利尤单抗联合R-CHOP治疗初治弥漫性大B细胞淋巴瘤。
  • 确定纳武利尤单抗最大耐受剂量后,治疗包括导入期纳武利尤单抗240 mg×1次,2周后给予纳武利尤单抗-R-CHOP联合方案,每3周1次,共6个周期。
  • 共入组33例患者,其中25例可评估毒性、22例可评估疗效。
  • 试验注册号:NCT03704714。

主要发现

  • 估计18个月总生存率为95.4%,估计18个月无进展生存率为72.7%。
  • 观察到的治疗相关不良事件与既往纳武利尤单抗和R-CHOP报告相比无显著差异。
  • 患者报告结局未提示在R-CHOP基础上加用纳武利尤单抗导致生活质量指标恶化。
  • 探索性生物学相关性分析显示,耗竭T细胞免疫表型是进展和免疫毒性的预测因素,同时提示预处理方法的有效性。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 20% of diffuse large B-cell lymphoma have aberrations involving the programmed death ligands 1 and 2 (PD-L1/PD-L2) locus. This justifies the investigation of PD-1 checkpoint inhibitors in the frontline therapy setting in a bid to improve outcomes, especially in patients with high-risk disease (antecedent low-grade lymphoma, MYC aberrancy, advanced staged disease, and intermediate/high-risk International Prognostic Index score). This phase 1b study evaluated the safety and preliminary efficacy of a combination of nivolumab and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) using a priming approach. Upon establishing the maximum tolerated dose of nivolumab, treatment consisted of a lead-in phase with nivolumab 240 mg × 1 followed 2 weeks later by combination nivolumab-R-CHOP given every 3 weeks for 6 cycles. A total of 33 patients were enrolled, of which 25 and 22 patients were evaluable for toxicity and efficacy, respectively. Estimated 18-month overall survival and progression-free survival rates were 95.4% and 72.7%, respectively. The observed therapy-related adverse events were not significantly different from previous reports on nivolumab and R-CHOP, respectively. Patient-reported outcomes did not suggest that the addition of nivolumab to R-CHOP led to worse quality of life measures. Exploratory analysis of biologic correlates showed an exhausted T-cell immunophenotype to be a predictor of progression and immunotoxicity, while also suggesting the effectiveness of a priming approach. This trial was registered at www.clinicaltrials.gov as #NCT03704714.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Odetola O, Ma S, Winter J, et al. Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy. Blood Adv. 2025. PMID: 40706069. doi:10.1182/bloodadvances.2025016298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。